Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for prevention of cerebral hyperperfusion syndrome after endovascular treatment in chronic stroke
ChiCTR1900024416Phase 4Completed
- Sponsor
- Henan Provincial People's Hospital
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dexmedetomidine in cerebrovascular disease and chronic cerebral hypoperfusion (CCH) (2 arms), sponsored by Henan Provincial People's Hospital. Primary endpoints: Cerebral hyperperfusion syndrome, Transcranial Doppler and 3 more. Started Jul 2019; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
cerebrovascular diseasechronic cerebral hypoperfusion (CCH)
Beyond the preview
Go deeper on ChiCTR1900024416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024416.